Friday, 27 Mar 2020

You are here

Risk of Multiple Sclerosis with TNF Inhibitor Therapy

Researchers from the DANBIO registry have linked their registry of 30,033 arthritis patients with the Danish Multiple Sclerosis Registry (DMSR) to identify all new multiple sclerosis cases occuring in arthritis patients and those receiving TNF inhibitors (TNFi). 

All MS cases were diagnosed by a neurologist with expertise in MS.  After excluding those with MS, a total of 27,880 arthritis pateints were analyzed. During the follow-up period 2000–2012, 10,294 started TNFi therapy. During 113,527 person-years, 12 incident MS cases occurred in the cohort, with a nonsignificant increase and overall SIR=1.11 (95% CI 0.63–1.96) (table 2).

An increased risk was seen in males treated with TNFi (SIR 3.48; 95% CI 1.45–8.37) and in patients with ankylosing spondylitis (AS) (SIR 3.91; 95% CI 1.47–10.42). The SIR for all patients with RA was 0.65 (95% CI 0.24–1.72). Risk was highest in the first 1-2 years of TNFi therapy, more in males, RA males and AS males patients.

We previously published findings of another Danish analysis suggesting that inflammatory bowel disease patients on TNFi had a two-fold increased risk of demyelinating disease.

In summary, these data suggest the risk of MS alone may differ according to cohort or disease and may be higher in men and after the first 1-2 years of TNFi therapy. The much wider spectrum of demyelinating disease may yield a greater risk in RA, as it did in IBD, but still merits further study. Mechanisms underlying such adverse events have not been elucidated. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Start with Anti-TNF in RA? Not So Fast

The suggestion to hit rheumatoid arthritis (RA) early and hard with biologic therapies itself took a hit in a new study.

Use of first-line etanercept (Enbrel) plus methotrexate in very early RA was not associated with a substantially higher rate of remission compared with a strategy of treat-to-target methotrexate monotherapy, a randomized open-label trial found.

Best of 2019 - The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Psoriasis Risk Increased with TNF Inhibitors in Juveniles

Children with inflammatory diseases who were treated with tumor necrosis factor (TNF) inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, a single-center retrospective study found.

The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Pain Persists Despite TNF Inhibitor Use

Control of pain in patients with rheumatoid arthritis (RA) often focuses on control of inflammation as a means to better control pain. However, a new claims data study shows that while anti-tumor necrosis factor inhibitor (TNFi) may lower the use of opioids, the reduction is nominal, suggesting that a substantial amount of pain is not adequately addressed by TNFi - a potent anti-inflammatory approach.